Galmed Pharma (GLMD) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts GLMD Hot Sheet
Join SI Premium – FREE
Galmed Pharma (NASDAQ: GLMD) reported Q2 EPS of ($0.26), $0.06 better than the analyst estimate of ($0.32).
For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADTRAN, Inc. (ADTN) Tops Q3 EPS by 5c; offers guidance
- Hillman Solutions (HLMN) Tops Q3 EPS by 1c; Offers Guidance
- Waystar Holding Corp. (WAY) Reports Q3 EPS of $0.44
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
